클로자핀 중단의 이유 = Reason for Clozapine Discontinuation

다국어 초록 (Multilingual Abstract)

Objectives : Approximately 30% of individuals diagnosed with schizophrenia suffer from treatment-resistant schizophrenia. Clozapine is underutilized in the management of treatment-resistant schizophrenia. To understand contributing factors, we analyzed the time course and causes of clozapine discontinuations that occurred over a 20-year period in a clinical setting.
Methods : The reasons for discontinuation and duration of clozapine treatment from a retrospective database of 138 patients with schizophrenia who had prescribed clozapine at least a month were reviewed, with the motives for discontinuation coded. The causes for termination were analyzed.
Results : Over two-thirds of the patient had ceased clozapine. The two most common causes for discontinuation were side-effects (50%), and own decision (30%). Somnolence accounted for 34% of all side-effects induced discontinuations. Hematological problems accounted for 23% of side-effect. The Maximal treatment dose of clozapine was higher in continuation group (442.36 mg) than in discontinuation group (397.26 mg). The CGI-S score when prescribing clozapine last was higher in discontinuation group than in continuous group. The patients who took atypical antipsychotics before clozapine tended to cease clozapine because of side-effects than who took typical agent.
Conclusion : Future studies should seek various methods to relieve side-effects of clozapine. Prospective researches using more objective tools are needed to clarify the reason for clozapine discontinuation.

참고문헌 (Reference)

1 Levine SZ, "Treatment response trajectories and antipsychotic medications:examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial" 137 : 141-146, 2012

2 Seabourne A, "The use of clozapine in South Manchester" 18 : 618-619, 1994

3 Hodgson R, "The use of atypical antipsychotics in the treatment of schizophrenia in North Staffordshire" 20 : 141-147, 2005

4 Scheepers FE, "The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics" 24 : 47-54, 2001

5 Ciudad A, "The Schizophrenia Outpatient Health Outcomes (SOHO)study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain" 23 : 1-7, 2008

6 Henneen J, "Suicidal risk during treatment with clozapine: a meta-analysis" 73 : 139-145, 2005

7 Newcomer JW, "Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review" 19 (19): 1-93, 2005

8 Taylor D, "Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-lasting injection" 94 : 165-167, 2009

9 Pai NB, "Reason for clozapine cessation" 125 : 39-44, 2012

10 Lewis SW, "Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia" 32 : 715-723, 2006

11 Krivoy A, "Predictors of clozapine discontinuation in patients with schizophrenia" 26 : 311-315, 2011

12 Wheeler A, "Outcomes for schizophrenia patients with clozapine treatment: how good does it get?" 23 : 957-965, 2009

13 Atkinson JM, "Outcome following clozapine discontinuation: a retrospective analysis" 68 : 1027-1030, 2007

14 Nielsen J, "Optimizing clozapine treatment" 123 : 411-422, 2011

15 Tuunainen A, "Newer atypical antipsychotic medication versus clozapine for schizophrenia" CD000966-, 2000

16 Glick ID, "Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach" 72 : 1616-1627, 2011

17 Young C, "Management of the adverse effects of clozapine" 24 : 381-390, 1998

18 Leucht S, "Maintenance treatment with antipsychotic drugs for schizophrenia" 5 : CD008016-, 2012

19 Laker MK, "Long-term outcome with clozapine:comparison of patients continuing and discontinuing treatment" 13 : 75-78, 1998

20 Zygmunt A, "Interventions to improve medication adherence in schizophrenia" 159 : 1653-1654, 2002

21 McEvoy JP, "Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment" 163 : 600-610, 2006

22 Lieberman JA, "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia" 353 : 1209-1223, 2005

23 Kahn RS, "Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial" 371 : 1085-1097, 2008

24 Davis MC, "Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients" 130 : 30-39, 2014

25 Fenton WS, "Determinants of medication compliance in schizophrenia: empirical and clinical findings" 23 : 637-651, 1997

26 Patel M, "Cross-sectional study of patients perspectives on adherence to antipsychotic medication: depot versus oral" 69 : 1548-1556, 2008

27 Szymanski SR, "Course of treatment response in first-episode and chronic schizophrenia" 153 : 519-525, 1996

28 Taylor M, "Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study" 69 : 240-245, 2008

29 Meltzer HY, "Clozapine: balancing safety with superior antipsychotic efficacy" 6 : 134-144, 2012

30 Lieberman JA, "Clozapine: Guidelines for clonical management" 50 : 329-338, 1989

31 Ciapparelli A, "Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder:a naturalistic 48-month follow-up study" 64 : 451-458, 2003

32 Kane J, "Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine" 45 : 789-796, 1988

33 Kane J, "Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine" 45 : 789-796, 1988

34 Clarke LA, "Clozapine augmentation with aripiprazole for negative symptoms" 67 : 675-676, 2006

35 Benedetti A, "Augmentation of clozapine with aripiprazole in severe psychotic bipolar and schizoaffective disorders: a pilot study" 6 : 30-35, 2010

36 Longden E, "Assessing and reporting the adverse effects of antipsychotic medication: A Systematic Review of clinical studies, and prospective retrospective, and cross-sectional research" 39 : 29-39, 2016

37 Haro JM, "Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia" 21 : 41-47, 2006

38 Leung JG, "Antipsychotic agents used to augment clozapine during long-term inpatient hospitalizations" 47 : 263-267, 2014

39 Howes OD, "Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation" 201 : 481-485, 2012

40 Munro J, "Active monitoring of 12,760 clozapine recipients in the UK and Ireland" 175 : 576-580, 1999

41 Fitzsimons J, "A review of clozapine safety" 4 : 731-744, 2005

42 Meltzer HY, "A prospective study of clozapine in treatment-resistant schizophrenia patients. I. Preliminary report" 99 : S68-S72, 1989

43 Hudson TJ, "A pilot study of barriers to medication adherence in schizophrenia" 65 : 211-216, 2004